EN | UA
EN | UA

Help Support

Back

Caffeine: A promising therapy for improving mobility and balance in multiple sclerosis

Multiple sclerosis Multiple sclerosis
Multiple sclerosis Multiple sclerosis

What's new?

Consuming caffeine daily could enhance balance and functional mobility in individuals with multiple sclerosis, showing noticeable effects within 2 weeks and sustained throughout 3 months.

Caffeine, a psychoactive agent proved to be effective in improving balance, mobility and quality of life (QoL) in people with multiple sclerosis (MS), as revealed from a clinical trial published in the ‘PLoS One’ journal. Interestingly, a significant increase in self-reported walking impairment over time was observed in men. Ageing plays a pivotal role in balance with time.

Afsoon Dadvar et al. assessed the possible consequences of caffeine consumption on balance, mobility and health-related QoL in people with MS.

This trial had a 2-week placebo run-in followed by a 12-week stage with 200 mg/day of caffeine. The Generalized Estimation Equation (GEE) was used to investigate the changes in outcome measures throughout the study. The different outcome measures used were:

  • Twelve-item Multiple Sclerosis Walking Scale (MSWS-12) to assess self-reported walking ability
  • Patients' Global Impression of Change (PGIC) for patient's impression of treatment efficacy
  • Berg Balance Scale (BBS) to assess balance (static and dynamic)
  • Timed Up and Go (TUG) to assess dynamic balance and functional movement
  • Multiple Sclerosis Impact Scale (MSIS-29) for QoL

The effect of age and gender outcome measures was also assessed with the help of GEE.

All in all, 30 individuals with MS (average age: 38.89 ± 9.85, female: 76.7%) were enrolled in the study. The intake of caffeine supplementation every day notably enhanced objective measures of balance and functional mobility at every time point (weeks 0, 2, 4, 8 and 12) along with subjective improvements in QoL observed 2 weeks after the supplementation.

No significant association was found concerning MSWS-12 and PGIC. The influence of age and gender on the outcome measures was also investigated, revealing substantial gender-time interaction effects for MSWS-12 (P-value = 0.001) and PGIC (P-value <0.001). Additionally, the influence of age on BBS scores increased over time.

Source:

PLoS One

Article:

Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial

Authors:

Afsoon Dadvar et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: